tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris announces publication of review article on bradykinin
The FlyPharvaris announces publication of review article on bradykinin
2d ago
PHVS
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
PremiumThe Fly
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
9d ago
AIG
AJG
Pharvaris initiated with an Overweight at Wells Fargo
PremiumThe Fly
Pharvaris initiated with an Overweight at Wells Fargo
9d ago
PHVS
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
PremiumCompany Announcements
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
28d ago
6K
PHVS
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
PremiumRatings
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
29d ago
PHVS
Pharvaris price target raised to $46 from $41 at Morgan Stanley
PremiumThe FlyPharvaris price target raised to $46 from $41 at Morgan Stanley
29d ago
PHVS
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
Premium
Ratings
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
1M ago
PHVS
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
Premium
Company Announcements
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
1M ago
6K
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
2M ago
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
2M ago
PHVS
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
PremiumRatings
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
2M ago
PHVS
Pharvaris price target raised to $33 from $31 at BofA
PremiumThe Fly
Pharvaris price target raised to $33 from $31 at BofA
2M ago
PHVS
Pharvaris price target lowered to $74 from $75 at Citizens
PremiumThe FlyPharvaris price target lowered to $74 from $75 at Citizens
2M ago
PHVS
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
Premium
The Fly
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
2M ago
PHVS
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
Premium
Company Announcements
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
2M ago
6K
PHVS
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
PremiumCompany Announcements
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
2M ago
6K
PHVS
Pharvaris price target raised to $31 from $30 at BofA
PremiumThe Fly
Pharvaris price target raised to $31 from $30 at BofA
2M ago
PHVS
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
PremiumRatings
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
3M ago
PHVS
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
PremiumThe Fly
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
3M ago
PHVS
Pharvaris price target raised to $52 from $48 at JonesResearch
PremiumThe FlyPharvaris price target raised to $52 from $48 at JonesResearch
3M ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
Premium
Ratings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
3M ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
Premium
Market News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
3M ago
ANET
BCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >